FDA
-
-
-
-
-
-
-
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
-
-
-
-
-
-
-
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
-
-
-
-
-
-
-
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
-
-
-
-
-
-
-
Innate Pharma Provides Update on Lacutamab Clinical Program
-
-
-
-
-
-
-
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
-
-
-
-
-
-
-
Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in Sézary Syndrome
-
-
-
-
-
-
-
Innate Pharma Announces Publication of EXPLORE COVID-19 Translational Study Findings in Nature
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

